MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simen, A. A.
Right arrow Articles by Miller, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simen, A. A.
Right arrow Articles by Miller, R. J.

Vol. 57, Issue 5, 1064-1074, May 2000

Involvement of Regions in Domain I in the Opioid Receptor Sensitivity of alpha 1B Ca2+ Channels

Arthur A. Simen and Richard J. Miller

Department of Neurobiology, Pharmacology, and Physiology, and Committee on Neurobiology, The University of Chicago, Chicago, Illinois

The structural basis of Ca2+ channel inhibition by G proteins has received considerable attention recently, and multiple regions on Ca2+ channels that interact with G protein subunits have been identified. We have demonstrated previously that a region extending from the N terminus to the I/II loop of the Ca2+ channel is involved in determining the differences between alpha 1B and alpha 1E Ca2+ channels with respect to inhibition by G proteins. Here we explore this region of the channel in greater detail in an effort to further define the regions involved in determining inhibition. Chimeric Ca2+ channels constructed from alpha 1B and alpha 1E Ca2+ channels revealed that the N terminus, the I/II loop, and domain I all play an important role in determining inhibition. We identified a 70-amino acid fragment from domain I that mediates the effects of domain I, and a 50-amino acid fragment from the I/II loop that mediates the effects of the I/II loop. When these regions from alpha 1B were exchanged into alpha 1E, inhibition identical with that of alpha 1B was observed. The differences between alpha 1B and alpha 1E in the identified region of domain I involve residues that are predicted to be almost exclusively extracellular. Mutations to some of the high-affinity G protein binding regions of alpha 1B (alpha  interaction domain, CC14, and a C-terminal Galpha binding site) caused relatively little change in inhibition, which suggests that these sites are not necessary individually for G protein-mediated inhibition and may help to explain the small effects of exchanging these regions in isolation.


Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
H. W. Tedford and G. W. Zamponi
Direct G Protein Modulation of Cav2 Calcium Channels
Pharmacol. Rev., December 1, 2006; 58(4): 837 - 862.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
B. Li, H. Zhong, T. Scheuer, and W. A. Catterall
Functional Role of a C-Terminal G{beta}{gamma}-Binding Domain of Cav2.2 Channels
Mol. Pharmacol., September 1, 2004; 66(3): 761 - 769.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Hummer, O. Delzeith, S. R. Gomez, R. L. Moreno, M. D. Mark, and S. Herlitze
Competitive and Synergistic Interactions of G Protein {beta}2 and Ca2+ Channel {beta}1b Subunits with Cav2.1 Channels, Revealed by Mammalian Two-hybrid and Fluorescence Resonance Energy Transfer Measurements
J. Biol. Chem., December 5, 2003; 278(49): 49386 - 49400.
[Abstract] [Full Text] [PDF]


Home page
JGPHome page
H. L. Agler, J. Evans, H. M. Colecraft, and D. T. Yue
Custom Distinctions in the Interaction of G-protein {beta} Subunits with N-type (CaV2.2) Versus P/Q-type (CaV2.1) Calcium Channels
J. Gen. Physiol., May 27, 2003; 121(6): 495 - 510.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
K. Melliti, M. Grabner, and G. R Seabrook
The familial hemiplegic migraine mutation R192q reduces G-protein-mediated inhibition of p/q-type (Cav2.1) calcium channels expressed in human embryonic kidney cells
J. Physiol., January 15, 2003; 546(2): 337 - 347.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
E. S. Piedras-Renteria, K. Watase, N. Harata, O. Zhuchenko, H. Y. Zoghbi, C. C. Lee, and R. W. Tsien
Increased Expression of alpha 1A Ca2+ Channel Currents Arising from Expanded Trinucleotide Repeats in Spinocerebellar Ataxia Type 6
J. Neurosci., December 1, 2001; 21(23): 9185 - 9193.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Safa, J. Boulter, and T. G. Hales
Functional Properties of CaV1.3 (alpha 1D) L-type Ca2+ Channel Splice Variants Expressed by Rat Brain and Neuroendocrine GH3 Cells
J. Biol. Chem., October 12, 2001; 276(42): 38727 - 38737.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
A. A. Simen, C. C. Lee, B. B. Simen, V. P. Bindokas, and R. J. Miller
The C Terminus of the Ca Channel {alpha}1B Subunit Mediates Selective Inhibition by G-Protein-Coupled Receptors
J. Neurosci., October 1, 2001; 21(19): 7587 - 7597.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Zhong, B. Li, T. Scheuer, and W. A. Catterall
Control of gating mode by a single amino acid residue in transmembrane segment IS3 of the N-type Ca2+ channel
PNAS, April 10, 2001; 98(8): 4705 - 4709.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. Y. Zhou, D. P. Siderovski, and R. J. Miller
Selective Regulation of N-Type Ca Channels by Different Combinations of G-Protein beta /gamma Subunits and RGS Proteins
J. Neurosci., October 1, 2000; 20(19): 7143 - 7148.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics